Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
Michael Thomas(University Hospital Heidelberg), Santiago Ponce-Aix(Research Institute Hospital 12 de Octubre), Alejandro Navarro(Vall d'Hebron Hospital Universitari), Jorge Riera‐Knorrenschild(Philipps University of Marburg), Manuel Schmidt(Mologen (Germany)), Emanuelly Varea Maria Wiegert(Mologen (Germany)), K. Kapp(Mologen (Germany)), B. Wittig(Mologen (Germany)), Claudia Mauri(University College London), M. Dómine Gómez(Hospital Universitario Fundación Jiménez Díaz), Jens Kollmeier(Helios Klinikum Emil von Behring), Parvis Sadjadian(Johannes Wesling Klinikum Minden), K.-P. Fröhling(Katholisches Klinikum Koblenz), RM Huber, M. Wolf(Klinikum Kassel), Georg Pall, Veerle Surmont, Leon Bosquée, Paul Germonpré, W. Brückl, C. Grah, Christian Herzmann, Rumo Leistner, Andreas Meyer, Lothar Müller, Oliver Schmalz, Christian W. Scholz, Michael Schröder, Monika Serke, Claas Wesseler, Christian Brandts, Hans‐Georg Kopp, Wolfgang Blau, Frank Griesinger, M.R. García Campelo, Yolanda García García, Jose M. Pérez
Cited by 81Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis